Clinical Trial Update: A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating the effect of Fluticasone/Formoterol Breath Actuated Inhaler versus Relvar Ellipta DPI on ventilation heterogeneity in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Fluticasone/Formoterol Breath Actuated Inhaler (fluticasone/formoterol)
• Relvar Ellipta (fluticasone furoate; vilanterol)

Snippet

Sponsor: Mundipharma Research Limited | Conditions: Asthma | Phase 3 | Status: COMPLETED